FDA Requires New Safety Warnings for Popular GLP-1 Drugs Due to Vision Loss Risk

The U.S. Food and Drug Administration (FDA) is mandating new safety warnings for all GLP-1 drugs, such as Wegovy and Zepbound, after identifying evidence of a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss. While a causal relationship has not yet been established, the agency is requiring the warnings.